Apellis Unveils 5-Year SYFOVRE Data, Redefining Hope for Vision Loss

WALTHAM, MA – February 19, 2026 – Apellis Pharmaceuticals is set to present landmark five-year data for its geographic atrophy (GA) treatment, SYFOVRE®, positioning the findings as a new benchmark in the fight against a leading cause of blindness. The company announced it will debut a comprehensive analysis from the GALE long-term extension study at the 49th Macula Society Annual Meeting in San Diego later this month, detailing the sustained effects of the first-ever approved therapy for this debilitating eye disease.

Geographic atrophy, an advanced form of age-related macular degeneration (AMD), affects over a million Americans, progressively destroying retinal cells and leading to irreversible vision loss. For years, patients and physicians had no approved options to slow its relentless advance. The upcoming presentation by Apellis promises to deliver the longest-term evidence to date on the benefits of early and continuous intervention.

“We look forward to sharing the five-year results from our GALE extension study, which show the importance of early treatment with SYFOVRE for preserving retinal tissue and delaying disease progression in patients with geographic atrophy,” said Caroline Baumal, M.D., chief medical officer at Apellis, in a company statement. “Backed by the largest GA data set with the longest follow-up, these new findings demonstrate the clinically meaningful impact that SYFOVRE can have for patients living with this devastating disease.”

A New Clinical Benchmark

The centerpiece of Apellis's presentation will be the oral session, “Earlier Treatment Yields Better Outcomes: 5-Years of Pegcetacoplan Treatment for Geographic Atrophy Secondary to AMD,” scheduled for February 27. The data, derived from the GALE extension of the pivotal OAKS and DERBY trials, is expected to show a durable effect in slowing the growth of GA lesions.

Post-hoc analysis of the five-year data indicates that continuous treatment with SYFOVRE provided a clinically meaningful reduction in GA lesion growth. Monthly injections reportedly reduced growth by 31%, while every-other-month dosing showed a 27% reduction compared to a projected sham arm. In more tangible terms, this slowing of the disease is equivalent to delaying GA progression by approximately 1.5 years for patients with nonsubfoveal GA, a significant timeframe for those facing progressive vision loss.

The findings reinforce the company’s message that early intervention is key. The analysis suggests that patients who began treatment earlier preserved more retinal tissue over the long term compared to those who started therapy two years later. This is a crucial point for a disease where damage is irreversible. The safety profile over the five-year period reportedly remained consistent with previous data, with no new safety signals emerging, though known risks such as intraocular inflammation and an increased rate of neovascular (wet) AMD remain important considerations for clinicians.

Navigating a Competitive Landscape

While SYFOVRE was the first to market in February 2023, it no longer stands alone. The GA treatment landscape has become a competitive arena with the approval of IZERVAY™ (avacincaptad pegol) in August 2023. Both drugs work by targeting the complement cascade—a part of the immune system implicated in GA progression—but they act on different proteins, with SYFOVRE inhibiting C3 and IZERVAY targeting C5.

This has created a dynamic market where retina specialists must weigh the merits of each therapy. While some indirect comparisons have suggested SYFOVRE may have a slight efficacy advantage, particularly in certain patient subgroups, real-world data and head-to-head trials are lacking. The five-year GALE data provides Apellis with a powerful marketing tool: the longest and largest dataset available for any GA treatment, arguing for a proven track record of sustained efficacy.

The market itself is poised for explosive growth, with some analysts projecting it to reach tens of billions of dollars by the early 2030s, driven by an aging global population and the introduction of these first-ever therapies. Apellis's robust long-term data could be critical in securing a dominant share of this burgeoning market, despite ongoing challenges from its primary competitor.

The View from the Clinic

The availability of treatments that can slow GA has been hailed as a monumental step forward, yet the clinical community remains divided. Many ophthalmologists have embraced the new therapies, offering them to patients as a way to finally fight back against the disease.

“For the first time, we can tell a patient that we have something that can alter the natural course of their disease,” noted one retinal specialist, speaking on the condition of anonymity. “Slowing it down by 30 or 40 percent might not sound like a cure, but over several years, that can mean the difference between maintaining independence and needing significant assistance.”

However, a sense of caution persists. Some physicians are more reserved, pointing out that the treatments slow the disease but do not stop its progression or restore lost vision. They argue that this modest benefit must be carefully weighed against the significant treatment burden of lifelong intravitreal injections and the potential for serious side effects, including the risk of intraocular inflammation and rare but severe retinal vasculitis associated with SYFOVRE.

“It’s a very personal decision between the doctor and the patient,” another clinician commented. “You have to balance the potential to preserve vision for a few more years against the risks and the reality of coming in for an injection every month or two. This new five-year data is encouraging, but it doesn't eliminate that complex calculus.”

A High-Stakes Presentation for Apellis

Beyond the clinical implications, the upcoming presentation carries significant weight for Apellis as a business. After an initial surge, SYFOVRE sales have faced headwinds from competition and the cautious uptake among some physicians. The company's stock currently holds a consensus "Hold" rating from analysts, reflecting uncertainty about its long-term growth trajectory.

This five-year data is Apellis's opportunity to re-energize momentum. By demonstrating a durable, long-term effect, the company can reinforce SYFOVRE’s value proposition to both clinicians and payers. The data serves as a powerful rebuttal to concerns about long-term efficacy and may help convince hesitant doctors of the treatment's benefits.

Investors will be watching the Macula Society meeting and the company’s upcoming fourth-quarter financial results call on February 24 with keen interest. The comprehensive GALE data represents a cornerstone of Apellis's strategy to establish SYFOVRE as the standard of care in GA and secure its financial future in a highly competitive and lucrative market.